Saturday 17 October 2026
Export CNTB’s income statement to Excel — free account
Connect Biopharma Holdings Limited Sponsored ADR
CNTB Healthcare Biotechnology
Connect Biopharma Holdings Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $64,000.00, down 99.8% from fiscal 2024. In the quarter to June 2026, revenue grew 296.6%, EPS fell 17.4%, free cash flow fell 23.5% and total debt fell 61.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.91
0.00
0.00%
Follow CNTB
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | 0.00 |
+8 more quarters Free account |
P/S ratio |
49.87 | 159.13 | — | 42.47 | |
P/FCF ratio |
0.00 | 0.00 | — | 0.00 | |
P/Operating CF |
(9.40) | (9.26) | — | (4.83) | |
P/B ratio |
5.57 | 3.48 | — | 1.52 | |
Price to Tangible BV |
5.58 | 3.48 | — | 1.52 | |
EV/Sales |
39.45 | 109.99 | — | 15.04 | |
EV/EBITDA |
0.00 | 0.00 | — | 0.00 | |
EV/Operating CF |
(1.95) | (1.79) | — | (0.70) | |
EV/FCF |
(1.94) | (1.78) | — | (0.69) | |
Quick Ratio |
2.37 | 3.23 | 3.74 | 5.48 | |
Current Ratio |
2.37 | 3.23 | 3.74 | 5.48 | |
Net Debt/EBITDA |
1.79 | 2.35 | 2.87 | 3.11 | |
Debt/Assets |
0.47% | 0.48% | 0.66% | 0.66% | |
Debt/Equity |
0.01 | 0.01 | 0.01 | 0.01 | |
Asset Turnover |
0.05 | 0.01 | 0.00 | 0.02 | |
Operating CF/Net income |
0.92 | 0.83 | 0.74 | 1.01 | |
Capex/Depreciation |
0.00 | 0.00 | (0.09) | (0.19) | |
Research and Development Expense of Revenue |
587.90% | 8,893.49% | 0.00% | 69,437.50% | |
Selling, General and Administrative Expense of Revenue |
148.09% | 2,808.28% | 0.00% | 41,143.75% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
45.56% | 709.47% | 0.00% | 5,725.00% | |
Graham Net Nets |
0.15 | 0.25 | — | 0.60 | |
Graham Number |
0.00 | 0.00 | — | 0.00 | |
Earnings Yield |
(50.00%) | (43.89%) | — | (59.03%) | |
Free Cash Flow Yield |
(40.77%) | (38.94%) | — | (51.12%) | |
Revenue per Share |
0.04 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.25) | (0.28) | (0.20) | (0.31) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.25) | (0.28) | (0.20) | (0.31) | |
Cash per Share |
0.50 | 0.81 | 0.80 | 0.98 | |
Shareholders Equity per Share |
0.43 | 0.75 | 0.75 | 0.99 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.43 | 0.75 | 0.75 | 0.99 | |
Free Cash Flow |
(15.92) | (16.00) | (11.27) | (17.44) | |
Working Capital |
22.32 | 37.98 | 37.32 | 51.17 | |
Capital Expenditures |
— | — | (0.02) | (0.03) | |
Net Current Asset Value |
22.01 | 37.58 | 36.83 | 50.61 | |
EV/EBIT |
0.00 | 0.00 | — | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 2.13 | |
Price to Operating Income |
0.00 | 0.00 | — | 0.00 | |
| Other line items | |||||
Average Receivables |
6.56 | 6.37 | 4.92 | 4.99 | |
Average Payables |
2.16 | 2.56 | 1.15 | 3.85 | |
Average Assets |
63.10 | 76.38 | 78.68 | 93.97 | |
Average Common Equity |
49.10 | 62.76 | 67.07 | 82.93 |
Columns are period end dates